NEW YORK (GenomeWeb) – Researchers from the Dana-Farber Cancer Institute and Resolution Biosciences have identified more actionable gene fusion mutations with higher allele frequencies in lung cancer patients using Resolution Bioscience's ctDx-Lung liquid biopsy test than using Guardant Health's Guardant360 assay.
GenomeWeb Premium gives you:
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Also in Industry News
CDC Coronavirus Testing Decision Likely to Haunt US for Months to Come
Cannabidiol helps fight antibiotic-resistant bacteria
Changes in surface sugarlike molecules help cancer cells to spread